Literature DB >> 20144434

Inspiratory efforts achieved in use of the Technosphere insulin inhalation system.

Chad C Smutney1, Emil M Friedman, John M Polidoro, Nikhil Amin.   

Abstract

OBJECTIVE: The Technosphere Insulin (TI) inhalation system comprises TI powder premetered into unit dose cartridges and the patient-friendly, reusable, breath-powered MedTone inhaler. This high-resistance system uses a patient's inspiratory effort to effect TI powder de-agglomeration and promote subsequent deep-lung delivery. This study reports on flow and pressure data achieved by patients with diabetes using the MedTone system.
METHOD: MedTone inhalers containing empty cartridges were adapted with pneumotach measuring devices to capture inhalation profiles. The measuring apparatuses had negligible impact on the nominal MedTone system resistance level of 0.117 kPa(0.5)/liters/min. Each of 56 subjects inhaled twice to mimic TI clinical study dosing instructions. Achieved inhalation profiles were characterized by peak inspiratory flow (PIF), peak inspiratory pressure (PIP), and average pressure drop from the time of PIP to 4 s (P(avg)).
RESULTS: The achieved mean PIF (+/- standard deviation [SD]) in all subjects was 26.74 (+/-6.06) liters/min after the first inhalation and was similar to the mean PIF of 26.25 (+/-6.23) liters/min achieved after the second inhalation. Mean PIP (+/-SD) achieved by subjects was 8.49 (+/-2.86) and 8.1 (+/-2.99) kPa, and mean P(avg) drop (+/-SD) in all subjects was 6.53 (+/-2.24) and 6.09 (+/-2.08) kPa after the respective inhalations.
CONCLUSION: Patients with diabetes demonstrated consistent inhalation efforts over two inhalations using the MedTone system. The achieved PIFs and PIPs demonstrate the capacity of this population to obtain sufficient inspiratory effort necessary for delivery of TI using the MedTone inhaler. Adequate postpeak pressures were also revealed, further supporting reliable and sustained inhalation efforts. 2009 Diabetes Technology Society.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20144434      PMCID: PMC2769892          DOI: 10.1177/193229680900300524

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  7 in total

Review 1.  Measuring agreement in method comparison studies.

Authors:  J M Bland; D G Altman
Journal:  Stat Methods Med Res       Date:  1999-06       Impact factor: 3.021

2.  Pulmonary insulin delivery by means of the Technosphere drug carrier mechanism.

Authors:  Andreas Pfützner; Thomas Forst
Journal:  Expert Opin Drug Deliv       Date:  2005-11       Impact factor: 6.648

3.  Single breath diffusing capacity in a representative sample of the population of Michigan, a large industrial state. Predicted values, lower limits of normal, and frequencies of abnormality by smoking history.

Authors:  A Miller; J C Thornton; R Warshaw; H Anderson; A S Teirstein; I J Selikoff
Journal:  Am Rev Respir Dis       Date:  1983-03

4.  Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes.

Authors:  Jay S Skyler; Lois Jovanovic; Sol Klioze; Joann Reis; William Duggan
Journal:  Diabetes Care       Date:  2007-03       Impact factor: 19.112

5.  Technosphere/Insulin--proof of concept study with a new insulin formulation for pulmonary delivery.

Authors:  S Steiner; A Pfützner; B R Wilson; O Harzer; L Heinemann; K Rave
Journal:  Exp Clin Endocrinol Diabetes       Date:  2002-01       Impact factor: 2.949

6.  Safety and efficacy of inhaled insulin (AERx iDMS) compared with subcutaneous insulin therapy in patients with Type 1 diabetes: 1-year data from a randomized, parallel group trial.

Authors:  R G Moses; P Bartley; H Lunt; R C O'Brien; T Donnelly; M-A Gall; A Vesterager; P Wollmer; A Roberts
Journal:  Diabet Med       Date:  2009-03       Impact factor: 4.359

7.  Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents.

Authors:  Julio Rosenstock; Richard Bergenstal; Ralph A Defronzo; Irl B Hirsch; David Klonoff; Anders H Boss; David Kramer; Richard Petrucci; Wen Yu; Brian Levy
Journal:  Diabetes Care       Date:  2008-08-04       Impact factor: 17.152

  7 in total
  2 in total

1.  Insulin lung deposition and clearance following Technosphere® insulin inhalation powder administration.

Authors:  James P Cassidy; Nikhil Amin; Mark Marino; Mark Gotfried; Thomas Meyer; Knut Sommerer; Robert A Baughman
Journal:  Pharm Res       Date:  2011-04-14       Impact factor: 4.200

2.  In Vitro Tests for Aerosol Deposition. IV: Simulating Variations in Human Breath Profiles for Realistic DPI Testing.

Authors:  Renishkumar R Delvadia; Xiangyin Wei; P Worth Longest; Jurgen Venitz; Peter R Byron
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2015-10-08       Impact factor: 2.849

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.